30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Gain Therapeutics Inc (GANX)

Track

Stock chart
Ticker: GANX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Mack Gene
CFO and Interim CEO
1 purchase — total 14,544 USD
Buy 9 Aug 2024
Value US$3,322,825.59 | Price 66.73 | Shares 15,602
Buy 9 Aug 2024
Value US$3,497,910.35 | Price 126.02 | Shares 71,610
Buy 1 Jul 2024
Value US$14,520.00 | Price 1.21 | Shares 12,000
Buy 1 Jul 2024
Value US$6,150.00 | Price 1.23 | Shares 5,000
Buy 28 Mar 2024
Value US$115,770.00 | Price 3.86 | Shares 30,000
Sale 21 Dec 2023
Value US$506.76 | Price 2.46 | Shares 206
Sale 7 Dec 2023
Value US$4,550.00 | Price 2.50 | Shares 1,820
Buy 25 May 2022
Value US$6,403.56 | Price 2.58 | Shares 2,482
Buy 20 May 2022
Value US$26,194.48 | Price 2.83 | Shares 9,256
Buy 19 May 2022
Value US$10,840.00 | Price 2.71 | Shares 4,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-08-12 2024-08-09 B Purchase
3.3
Mack Gene

CFO and Interim CEO

Officer
15,602 -15.9%
66.73
US$3,322,826 		15,602 -15.9% 66.73 US$3,322,826
2024-08-12 2024-08-09 B Purchase
3.3
Islam Khalid

Executive Chairman

Executive Director
71,610 +25.3%
126.02
US$3,497,910 		71,610 +25.3% 126.02 US$3,497,910
2024-07-01 2024-07-01 B Purchase
3.8
RICHMAN ERIC I
Non-Executive Director
67,802 +22.7%
162.61
US$1,229,142 		67,802 +22.7% 162.61 US$1,229,142
2024-07-01 2024-07-01 B Purchase
3.8
RICHMAN ERIC I
Non-Executive Director
5,000 +1.8%
1.23
US$6,150 		5,000 +1.8% 1.23 US$6,150
2024-04-01 2024-03-28 B Purchase
0.5
Riley Jeffrey Scott
Non-Executive Director
30,000 +inf%
3.86
US$115,770 		30,000 +inf% 3.86 US$115,770
2023-12-22 2023-12-21 S Sale
0.9
Alder Matthias

Chief Executive Officer

Executive Director
206 -3.8%
2.46
US$507 		206 -3.8% 2.46 US$507
2023-12-14 2023-12-07 S Sale
0.9
Alder Matthias

Chief Executive Officer

Executive Director
1,820 -27.3%
2.50
US$4,550 		1,820 -27.3% 2.50 US$4,550
2022-05-27 2022-05-25 B Purchase
3.8
RICHMAN ERIC I

CHIEF EXECUTIVE OFFICER

Executive Director
2,482 +1.2%
2.58
US$6,404 		2,482 +1.2% 2.58 US$6,404
2022-05-23 2022-05-20 B Purchase
3.8
RICHMAN ERIC I

CHIEF EXECUTIVE OFFICER

Executive Director
9,256 +4.5%
2.83
US$26,194 		9,256 +4.5% 2.83 US$26,194
2022-05-23 2022-05-19 B Purchase
3.8
RICHMAN ERIC I

CHIEF EXECUTIVE OFFICER

Executive Director
4,000 +2.0%
2.71
US$10,840 		4,000 +2.0% 2.71 US$10,840
Explore more

More insider trading research around Gain Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America